Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.71 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.66 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.66 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.56 |
| ▸ | SDHB | P21912 | 1/20 | 0.56 |
| ▸ | STAT3 | P40763 | 1/20 | 0.56 |
| ▸ | STAT1 | P42224 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18527435 | 0.83 | HSD17B10 (0.71) | KDM4EHSD17B10ALDH1A1ADORA2AADORA1 | |
| SCHEMBL4904514 | 0.80 | ADORA2A (1.00) | KDM4EHSD17B10ALDH1A1ADORA2AADORA1 | |
| SCHEMBL2849715 | 0.79 | HSD17B10 (0.65) | KDM4EHSD17B10ALDH1A1ADORA2AMAPK1 | |
| SCHEMBL2849704 | 0.79 | MEN1 (0.66) | KDM4EHSD17B10ALDH1A1ADORA2AMAPK1 | |
| SCHEMBL28496965 | 0.78 | HSD17B10 (0.64) | KDM4EHSD17B10ALDH1A1ADORA2AMAPK1 | |
| SCHEMBL5785867 | 0.78 | PTGS2 (1.00) | KDM4EHSD17B10ALDH1A1PTGS2RAB9A | |
| SCHEMBL19417246 | 0.77 | ADORA2A (0.91) | KDM4EHSD17B10ALDH1A1ADORA2AADORA1 | |
| SCHEMBL10900625 | 0.76 | HSP90AA1 (0.71) | KDM4EHSD17B10ALDH1A1ADORA2AADORA1 | |
| SCHEMBL5750164 | 0.76 | KDM4E (0.60) | KDM4EHSD17B10ALDH1A1PTGS2NPSR1 | |
| SCHEMBL28145393 | 0.76 | ADORA2A (0.73) | KDM4EHSD17B10ALDH1A1ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11560391-B2 | Sulfonylurea compounds as inhibitors of interleukin-1 activity | GENENTECH, INC. (US) | 2023-01-24 | — | — | US | disclosed |
| EP-3823726-A1 | SULFONYLUREA COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | F. Hoffmann-La Roche SA (CH) | 2021-05-26 | — | — | EP | disclosed |
| CN-112437683-A | Sulfonylurea compounds useful as inhibitors of interleukin-1 activity | 豪夫迈·罗氏有限公司 | 2021-03-02 | — | — | CN | disclosed |
| WO-2020018970-A1 | SULFONYLUREA COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | GENENTECH, INC. (US) | 2020-01-23 | — | — | WO | disclosed |
| US-20150259329-A1 | NOVEL HETEROCYCLE COMPOUNDS AND USES THEREOF | INTRA CELLULAR THERAPIES INC (US) | 2015-09-17 | — | — | US | disclosed |
| US-9056837-B2 | Heterocycle compounds and uses thereof | INTRA-CELLULAR THERAPIES, INC. (US) | 2015-06-16 | — | — | US | disclosed |
| US-20130123269-A1 | NOVEL HETEROCYCLE COMPOUNDS AND USES THEREOF | INTRA-CELLULAR THERAPIES, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-8367686-B2 | Heterocycle compounds and uses thereof | INTRA-CELLULAR THERAPIES, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20100173924-A1 | NOVEL HETEROCYCLE COMPOUNDS AND USES THEREOF | INTRA-CELLULAR THERAPIES INC. | 2010-07-08 | — | — | US | disclosed |
| EP-2166858-A1 | NOVEL HETEROCYCLE COMPOUNDS AND USES THEREOF | Intra-Cellular Therapies, Inc. (US) | 2010-03-31 | — | — | EP | disclosed |
| WO-2008153959-A1 | NOVEL HETEROCYCLE COMPOUNDS AND USES THEREOF | INTRA-CELLULAR THERAPIES, INC. (US) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150259329-A1 | NOVEL HETEROCYCLE COMPOUNDS AND USES THEREOF | PYGB, BACE1, APP | KDM4E 3588/4885HSD17B10 1340/4885ALDH1A1 2057/4885 |
| US-20100173924-A1 | NOVEL HETEROCYCLE COMPOUNDS AND USES THEREOF | PYGB, BACE1, APP | KDM4E 3515/4885HSD17B10 1420/4885ALDH1A1 2149/4885 |
| US-20130123269-A1 | NOVEL HETEROCYCLE COMPOUNDS AND USES THEREOF | PYGB, BACE1, APP | KDM4E 3588/4885HSD17B10 1340/4885ALDH1A1 2057/4885 |
| US-11560391-B2 | Sulfonylurea compounds as inhibitors of interleukin-1 activity | IL1B, IL1A, IL18 | KDM4E 4310/4885HSD17B10 2597/4885ALDH1A1 1315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.